Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study

View Full Paper
Ask AI
Bookmark
Share

Authors

LQLihua QiuFLFei Li

Discussion

Loading...

Member takes

Overview

Prospective trial demonstrates improved efficacy and manageable safety profile of sonrotoclax, zanubrutinib in untreated mantle cell lymphoma.

Key Points

  • Eighty-six percent of patients exhibited complete remission in preliminary evaluation.
  • Among 30 patients treated, incidence of serious adverse events was limited to 6.7%.
  • Observational analysis in a prospective trial showed manageable toxicity after triplet therapy.
  • Efficacy in achieving minimal residual disease status suggests further exploration of this regimen.

Cite This Study

Qiu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e12ahttps://doi.org/10.1182/blood-2025-1809
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study2025 · 1 citations
  2. 2Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-1012025
  3. 3Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study2025 · 6 citations
  4. 4MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  5. 5Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025